First-or second-line therapy with gefitinib produces equal survival in non–small cell lung cancer
JY Wu, CJ Yu, CH Yang, SG Wu, YH Chiu… - American journal of …, 2008 - atsjournals.org
Rationale: Gefitinib is effective in treating patients with non–small cell lung cancer (NSCLC)
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
First-or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
JY Wu, CJ Yu, CH Yang, SG Wu, YH Chiu… - American Journal of …, 2008 - europepmc.org
Objectives To clarify the influence of gefitinib timing, we conducted a study to compare the
outcomes of different lines of gefitinib treatment in patients with exon 19 deletions or L858R …
outcomes of different lines of gefitinib treatment in patients with exon 19 deletions or L858R …
[引用][C] First-or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer
JY Wu, CJ Yu, CH Yang, SG Wu, YH Chiu… - American Journal of …, 2008 - cir.nii.ac.jp
First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell
Lung Cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データを …
Lung Cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データを …
[PDF][PDF] First-or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer
Am J Respir Crit Care Med, 2008 - researchgate.net
Objectives: To clarify the influence of gefitinib timing, we conducted a study to compare the
outcomes of different lines of gefitinib treatment in patients with exon 19 deletions or L858R …
outcomes of different lines of gefitinib treatment in patients with exon 19 deletions or L858R …
[引用][C] First-or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
JY Wu, CJ Yu, SG Wu, YH Chiu, CH Gow… - American journal of …, 2008 - ntur.lib.ntu.edu.tw
臺灣機構典藏NTUR:Item 246246/224771 English | 正體中文 | 简体中文 | 全文筆數/總筆數:
85126/222854 (38%) 造訪人次: 25537514 線上人數: 1111 RC Version 7.0 © Powered By DSPACE …
85126/222854 (38%) 造訪人次: 25537514 線上人數: 1111 RC Version 7.0 © Powered By DSPACE …
[引用][C] First-or Second-line Therapy with Gefitinib Produces Equal Survival in Non-Small Cell Lung Cancer
JY WU, CJ YU, PC YANG, CH YANG… - American journal of …, 2008 - pascal-francis.inist.fr
First-or Second-line Therapy with Gefitinib Produces Equal Survival in Non-Small Cell Lung
Cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
Cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
First-or Second-line Therapy with Gefitinib Produces Equal Survival in Non-Small Cell Lung Cancer
JY Wu, CJ Yu, CH Yang, SG Wu… - American Journal of …, 2008 - search.proquest.com
Gefitinib is effective in treating patients with non-small cell lung cancer (NSCLC) with
epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
[PDF][PDF] First-or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer
Am J Respir Crit Care Med, 2008 - academia.edu
Objectives: To clarify the influence of gefitinib timing, we conducted a study to compare the
outcomes of different lines of gefitinib treatment in patients with exon 19 deletions or L858R …
outcomes of different lines of gefitinib treatment in patients with exon 19 deletions or L858R …
First-or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
JY Wu, CJ Yu, CH Yang, SG Wu… - … of respiratory and …, 2008 - pubmed.ncbi.nlm.nih.gov
Rationale Gefitinib is effective in treating patients with non-small cell lung cancer (NSCLC)
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
[PDF][PDF] First-or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer
Am J Respir Crit Care Med, 2008 - academia.edu
Objectives: To clarify the influence of gefitinib timing, we conducted a study to compare the
outcomes of different lines of gefitinib treatment in patients with exon 19 deletions or L858R …
outcomes of different lines of gefitinib treatment in patients with exon 19 deletions or L858R …